📰 Axol Bioscience News
Page 2 - Axol Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Axol Bioscience. Real-time updates on events, politics, business and more.
June 7, 2023
Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ - News - PharmaTimes
April 5, 2023
/PRNewswire/ -- The "Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms...
February 21, 2023
DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global induced pluripotent stem cell (ipsc) market will grow from $2.69 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.5...
February 13, 2023
/PRNewswire/ -- The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to...
November 28, 2022
/PRNewswire/ -- Polaris Market Research recently published [115+ Pages] research report on "Cell Reprogramming Market Share, Size, Trends, Industry Analysis...
November 28, 2022
In this interview, we speak to Axol Bioscience about their human iPSC-derived cells and how they have the potential to revolutionize the field of neurodegenerative disease.
July 28, 2022
/PRNewswire/ -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added...
June 9, 2022
At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.
June 8, 2022
Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.
June 7, 2022
Comprehensive in vitro pro-arrhythmia assay used to validate Axol's cardiomyocytes for cardiac safety testing Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and